

## Generic Prospective Pipeline Summary

### Launch Expected 2010 to 2014 - Sorted by Year and Quarter

**Disclaimer:** The information contained herein is compiled from a variety of sources and is provided for informational purposes only. Due to circumstances beyond Caremark's control, information related to prospective drug launch dates is subject to change without notice. This information should not be solely relied upon for decision making purposes. Products containing a Paragraph IV certification inherently involve risks and uncertainties that cannot be predicted or quantified. Actual results may differ from those expressed or implied in this report depending upon a number of factors. These factors include: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non-infringement of patents covering products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; and the ability of competitors to extend exclusivity periods for their products.

| Trade Name                     | Therapeutic Class                         | Manufacturer         | Potential Launch           | US Brand Sales (\$M) |
|--------------------------------|---|----------------------|----------------------------|----------------------|
| <b>2010</b>                    |   |                      |                            |                      |
| Axid Solution                  | Histamine H2-receptor inhibitors          | Braintree            | Launched - 1/01/2010       | \$14                 |
| Mirapex                        | Antiparkinsonian Agents                   | Boehringer           | Launched - 1/04/2010       | \$510                |
| Corvert                        | Antiarrhythmics Type III                  | Pfizer               | Launched - 2/02/2010       | \$14                 |
| Aldara Topical Cream           | Immunomodulating Agents - Topical         | Imiquimod            | Launched - 2/26/2010       | \$366                |
| Flomax 24 Hour ER              | 5-Alpha Reductase Inhibitors              | Boehringer Ingelheim | Launched - 3/02/2010       | \$2,102              |
| Cardizem LA                    | Calcium Channel Blockers                  | Biovail              | Launched - 3/15/2010       | \$92                 |
| Prozac Weekly                  | (SSRIs)                                   | Eli Lilly            | Launched - 3/24/2010       | \$17                 |
| Skelaxin                       | Central Muscle Relaxants                  | King Pharma          | Launched - 3/31/2010       | \$481                |
| Cozaar                         | Angiotensin II Receptor Antagonists       | Merck                | Launched - 4/06/2010       | \$948                |
| Hyzar                          | Thiazides                                 | Merck                | Launched - 4/06/2010       | \$689                |
| Pepcid Soln                    | H-2 Antagonists                           | Salix                | Launched - 5/28/2010       | \$33                 |
| Yaz                            | Combination Contraceptives - Oral         | Bayer                | Limited Supply - 6/1/2010  | \$772                |
| Differin 0.1%                  | Acne Products                             | Galderma             | Launched - 6/02/2010       | \$86                 |
| Sular                          | Calcium Channel Blockers                  | Shionogi             | Launched - 6/9/2010        | \$86                 |
| Astelin                        | H1-receptor antagonists                   | Medpointe            | Launched - 6/24/2010       | \$210                |
| Arimidex                       | Aromatase Inhibitors                      | AstraZeneca          | Launched - 6/28/2010       | \$927                |
| Tarka                          | Antihypertensive Combinations             | Abbott               | Launched - 6/30/2010       | \$59                 |
| Exelon                         | Antidementia Agents                       | Novartis             | Launched - 7/01/2010       | \$428                |
| Zegerid                        | Ulcer Therapy Combinations                | Schering             | Launched - 7/01/2010       | \$194                |
| Effexor XR                     | Norepinephrine Reuptake Inhibitors        | Wyeth                | Launched - 7/01/2010       | \$2,732              |
| AmERGE                         | 5-HT(1)                                   | GlaxoSmithKline      | Launched - 7/08/2010       | \$60                 |
| Lovenox Subcutaneous Solution  | Heparins And Heparinoid-Like Agents       | Aventis              | Limited Supply - 7/26/2010 | \$2,753              |
| Methylin Soln                  | Stimulants - Misc.                        | Shinogi              | Launched - 7/29/2010       | \$8                  |
| Sanctura                       | Urinary Antispasmodics                    | Allergan             | Launched - 8/16/2010       | \$26                 |
| Diastat                        | Anticonvulsants - Benzodiazepines         | Valeant              | Launched - 9/01/2010       | \$6                  |
| Diastat Acudial                | Anticonvulsants - Benzodiazepines         | Valeant              | Launched - 9/01/2010       | \$97                 |
| Opana                          | Opioid Agonists                           | Endo                 | Launched - 9/29/2010       | \$74                 |
| Evoclin                        | Acne Products                             | Stiefel              | Launched - 10/01/2010      | \$41                 |
| Tussionex                      | Cough/Cold/Allergy Combinations           | UCB                  | Launched - 10/05/2010      | \$197                |
| Mirapex (0.75MG)               | Antiparkinsonian Agents                   | Boehringer-Ingelheim | Launched - 10/11/2010      | \$5                  |
| Ambien CR 6.25MG               | Non-Barbiturate Hypnotics                 | Sanofi Aventis       | Launched - 10/14/2010      | \$127                |
| Prevacid Solutab               | Antiluler Agents - Proton Pump Inhibitors | Abbott (TAP)         | Launched - 10/15/2010      | \$404                |
| Gemzar                         | Antimetabolites                           | Eli Lilly            | Launched - 11/15/10        | \$806                |
| Accolate                       | Leukotriene Modulators                    | Astra Zeneca         | Launched - 11/19/2010      | \$51                 |
| Aricept Tablet                 | Cholinomimetics - ACHE Inhibitors         | Eisai                | Launched - 11/29/2010      | \$2,401              |
| Aricept ODT                    | Cholinomimetics - ACHE Inhibitors         | Eisai                | Launched - 11/29/2010      | \$9                  |
| Xyzal                          | Antihistamines - Non-Sedating             | Sanofi Aventis       | Launched - 11/29/2010      | \$223                |
| Ambien CR 12.5MG               | Non-Barbiturate Hypnotics                 | Sanofi Aventis       | Launched - 12/06/2010      | \$807                |
| Hycamtin Injection             | Topoisomerase I Inhibitors                | GlaxoSmithKline      | Launched - 12/15/2010      | \$157                |
| Quixin                         | Ophthalmic Anti-infectives                | Vistakon             | Launched - 12/29/2010      | \$2                  |
| <b>2011</b>                    |   |                      |                            |                      |
| Lotrel 5-40, 10-40             | Antihpyertensive Combinations             | Novartis             | Launched - 1/3/2011        | \$313                |
| Rythmol SR                     | Antiarrhythmics Type I-C                  | GlaxoSmithKline      | Launched - 1/3/2011        | \$121                |
| Xodol                          | Opioid Combinations                       | Victory Pharma       | Launched - 1/27/2011       | \$11                 |
| Allegra D-24 Hour              | Cough/Cold/Allergy Combinations           | Sanofi Aventis       | Launched - 1/28/2011       | \$144                |
| Vfend                          | Imidazole-Related Antifungals             | Pfizer               | Launched - 2/15/2011       | \$183                |
| Femhrt                         | Estrogen Combinations                     | Pfizer               | Launched - 2/17/2011       | \$30                 |
| Neurontin                      | Anticonvulsants - Misc.                   | Pfizer               | Launched - 2/22/2011       | \$14                 |
| Xalatan Ophthalmic             | Ophthalmic Agents - Antiglaucoma Agents   | Pfizer               | Launched - 3/22/2011       | \$685                |
| Femcon FE                      | Combination Contraceptives - Oral         | Warner Chilcott      | Launched - 3/25/2011       | \$52                 |
| Aromasin                       | Aromatase Inhibitors                      | Pfizer               | Launched - 4/1/2011        | \$159                |
| Femara                         | Aromatase Inhibitors                      | Novartis             | Launched - 4/22/11         | \$669                |
| Concerta                       | Stimulants - Misc.                        | Ortho McNeil Pharma  | Launched - 5/2/11          | \$1,384              |
| Elestat                        | Ophthalmics - Misc.                       | Allergan             | Launched - 5/2/11          | \$34                 |
| Xibrom                         | Ophthalmics - Misc.                       | Ista                 | Launched - 5/13/11         | \$122                |
| Amrix ER                       | Central Muscle Relaxants                  | Anesta               | Launched - 5/13/11         | \$123                |
| Carbatrol                      | Anticonvulsants - Misc.                   | Shire US Inc.        | Launched - 5/20/11         | \$112                |
| Furdantin                      | Urinary Anti-infectives                   | Shionogi             | Launched - 5/23/11         | \$40                 |
| Adoxa                          | Tetracyclines                             | Pharmaderm           | Launched - 6/1/11          | \$7                  |
| Activella                      | Estrogen Combinations                     | Novo Nordisk         | Launched 6/9/11            | \$23                 |
| Nasacort AQ                    | Nasal Steroids                            | Sanofi-Aventis       | Launched 6/15/11           | \$250                |
| Levaquin Intravenous Solution  | Antinefactive Agents - Fluoroquinolones   | Ortho McNeil Pharma  | Launched 6/20/11           | \$158                |
| Levaquin Oral Solution         | Antinefactive Agents - Fluoroquinolones   | Ortho McNeil Pharma  | Launched 6/20/11           | \$6                  |
| Levaquin Tabs                  | Antinefactive Agents - Fluoroquinolones   | Ortho McNeil Pharma  | Launched 6/20/11           | \$1,514              |
| Entecort EC                    | Glucocorticosteroids                      | AstraZeneca          | Launched 6/23/11           | \$318                |
| Malarone 250-100 MG            | Antimalarial Combinations                 | GlaxoSmithKline      | 2011-Q3 (Settlement)       | \$67                 |
| Opana ER (7.5, 15)             | Opiate Agonists                           | Endo                 | 2011-Q3 (Settlement)       | \$18                 |
| Tegretol XR (100MG)            | Anticonvulsants - Misc.                   | Novartis             | 2011-Q3*                   | \$8                  |
| Caduet                         | Cardiovascular Agents- Combination        | Pfizer               | 2011-Q4 (Settlement)       | \$384                |
| Combivir                       | Antihypertensive Agents and Antilipemics  | GlaxoSmithKline      | 2011-Q4 (Settlement)       | \$337                |
| Lipitor                        | Antiretrovirals                           | Pfizer               | 2011-Q4 (Settlement)       | \$7,272              |
| Symbax                         | Inhibitors                                | Eli Lilly            | 2011-Q4*                   | \$88                 |
| Zyprexa                        | Selective Serotonin-reuptake Inhibitors   | Eli Lilly            | 2011-Q4*                   | \$2,915              |
| Zyprexa Intramuscular Solution | Atypical Antipsychotics                   | Eli Lilly            | 2011-Q4*                   | \$10                 |
| Zyprexa Zydis ODT              | Atypical antipsychotics                   | Eli Lilly            | 2011-Q4*                   | \$326                |
| <b>2012</b>                    |   |                      |                            |                      |
| Anzemet                        | 5-HT3 Receptor Antagonists                | Aventis              | 2012-Q1*                   | \$8                  |

## Generic Prospective Pipeline Summary

### Launch Expected 2010 to 2014 - Sorted by Year and Quarter

**Disclaimer:** The information contained herein is compiled from a variety of sources and is provided for informational purposes only. Due to circumstances beyond Caremark's control, information related to prospective drug launch dates is subject to change without notice. This information should not be solely relied upon for decision making purposes. Products containing a Paragraph IV certification inherently involve risks and uncertainties that cannot be predicted or quantified. Actual results may differ from those expressed or implied in this report depending upon a number of factors. These factors include: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non-infringement of patents covering products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; and the ability of competitors to extend or renew exclusivity periods for their products.

| Trade Name                     | Therapeutic Class                                     | Manufacturer         | Potential Launch     | US Brand Sales (\$M) |
|--------------------------------|---|----------------------|----------------------|----------------------|
| Anzemet Intravenous Solution   | 5-HT3 Receptor Antagonists                            | Aventis              | 2012-Q1*             | \$16                 |
| Avalide                        | Antihypertensive Combinations                         | BMS                  | 2012-Q1*             | \$408                |
| Avandamet                      | Antidiabetic Combinations                             | GlaxoSmithKline      | 2012-Q1 (Settlement) | \$196                |
| Avandaryl                      | Antidiabetic Combinations                             | GlaxoSmithKline      | 2012-Q1 (Settlement) | \$43                 |
| Avandia                        | Insulin Sensitizing Agents                            | GlaxoSmithKline      | 2012-Q1 (Settlement) | \$399                |
| Avapro                         | Angiotensin II Receptor Antagonists                   | BMS                  | 2012-Q1*             | \$492                |
| Clarinex Reditabs              | Antihistamines - Non-Sedating                         | Schering             | 2012-Q1 (Settlement) | \$7                  |
| Kepra XR                       | Neurological Agents - Anticonvulsants                 | UCB                  | 2012-Q1*             | \$135                |
| Lexapro                        | Selective Serotonin Reuptake Inhibitors (SSRIs)       | Forest               | 2012-Q1*             | \$2,779              |
| Lexapro Oral Solution          | Selective Serotonin Reuptake Inhibitors (SSRIs)       | Forest               | 2012-Q1*             | \$4                  |
| Seroquel                       | Dibenzapines  | AstraZeneca          | 2012-Q1*             | \$4,336              |
| Lescol                         | HMG CoA Reductase Inhibitors                          | Novartis             | 2012-Q2*             | \$33                 |
| Plavix                         | Platelet Aggregation Inhibitors                       | Bristol-Myers Squibb | 2012-Q2*             | \$6,053              |
| Provigil                       | Stimulants - Misc.                                    | Cephalon             | 2012-Q2*             | \$1,108              |
| Stalevo (100,150)              | Antiparkinson Dopaminergics                           | Novartis             | 2012-Q2 (Settlement) | \$93                 |
| Viramune                       | Antiretrovirals                                       | Boehringer-Ingelheim | 2012-Q2*             | \$145                |
| Viramune Oral Suspension       | Antiretrovirals                                       | Boehringer-Ingelheim | 2012-Q2*             | \$1                  |
| Actos                          | Antidiabetic;   | Takeda               | 2012-Q3 (Settlement) | \$3,525              |
| Adenoscan                      | Insulin Sensitizer                                    | Astellas             | 2012-Q3 (Settlement) | \$77                 |
| Clarinex                       | Diagnostic Drugs                                      | Schering             | 2012-Q3 (Settlement) | \$209                |
| Detrol LA                      | Antihistamines - Non-Sedating                         | Pfizer               | 2012-Q3*             | \$814                |
| Detrol Tabs                    | Urinary Antispasmodics                                | Pfizer               | 2012-Q3*             | \$66                 |
| Diovan                         | Urinary Antispasmodics                                | Novartis             | 2012-Q3*             | \$1,877              |
| Diovan HCT                     | Angiotensin II Receptor Antagonists                   | Novartis             | 2012-Q3*             | \$1,634              |
| Geodon Caps                    | Antihypertensive Combinations                         | Pfizer               | 2012-Q3*             | \$1,272              |
| Opana ER (5,10,20,30,40)       | Antipsychotics - Misc.                                | Endo                 | 2012-Q3 (Settlement) | \$314                |
| Revatio                        | Opioid Agonists                                       | Pfizer               | 2012-Q3*             | \$269                |
| Singulair                      | Pulmonary Hypertension - Phosphodiesterase Inhibitors | Merck                | 2012-Q3*             | \$2,974              |
| Singulair Oral Packet          | Leukotriene Modulators                                | Merck                | 2012-Q3*             | \$55                 |
| Singulair Oral Tablet Chewable | Leukotriene Modulators                                | Merck                | 2012-Q3*             | \$984                |
| Tricor 145 MG                  | Leukotriene Modulators                                | Abbott               | 2012-Q3 (Settlement) | \$1,323              |
| Xopenex UDV                    | Fibric Acid Derivatives                               | Spracor              | 2012-Q3 (Settlement) | \$491                |
| Actoplus Met                   | Sympathomimetics                                      | Takeda               | 2012-Q4 (Settlement) | \$484                |
| Claritin-D 12 Hour             | Antidiabetic Combinations                             | Schering             | 2012-Q4 (Settlement) | \$14                 |
| Claritin-D 24 Hour             | Cough/Cold/Allergy Combinations                       | Schering             | 2012-Q4 (Settlement) | \$21                 |
| Comtan                         | Cough/Cold/Allergy Combinations                       | Novartis             | 2012-Q4 (Settlement) | \$96                 |
| Evoxac                         | Antiparkinson Dopaminergics                           | Daiichi              | 2012-Q4 (Settlement) | \$52                 |
| Invega                         | Misc. Throat Products                                 | Janssen              | 2012-Q4*             | \$383                |
| Maxalt                         | Benzisoxazoles  | Merck                | 2012-Q4*             | \$274                |
| Maxalt MLT                     | Serotonin Agonists                                    | Merck                | 2012-Q4*             | \$219                |
| Requip XL                      | Serotonin Agonists                                    | GlaxoSmithKline      | 2012-Q4*             | \$57                 |
| Stalevo (no 100,150)           | Antiparkinson Dopaminergics                           | Novartis             | 2012-Q4 (Settlement) | \$46                 |
| <b>2013</b>                    |   |                      |                      |                      |
| Embeda                         | Narcotic Analgesics                                   | King Pharma          | 2013-Q1*             | \$63                 |
| Luxiq                          | Corticosteroids - Topical                             | Stiefel              | 2013-Q1 (Settlement) | \$34                 |
| Nimbex                         | Central Muscle Relaxants                              | Abbott               | 2013-Q1*             | \$38                 |
| Propecia                       | Hair Growth Agents                                    | Merck                | 2013-Q1 (Settlement) | \$95                 |
| Reclast                        | Calcium Regulators - Misc.                            | Novartis             | 2013-Q1*             | \$395                |
| Zometa                         | Calcium Regulators - Misc.                            | Novartis             | 2013-Q1*             | \$767                |
| Patanase                       | Nasal Antiallergy                                     | Alcon                | 2013-Q2*             | \$63                 |
| Zomig                          | Serotonin Agonists                                    | AstraZeneca          | 2013-Q2*             | \$182                |
| Zomig ZMT                      | Serotonin Agonists                                    | AstraZeneca          | 2013-Q2*             | \$36                 |
| Advicor                        | HMG CoA Reductase Inhibitors                          | Abbott               | 2013-Q3 (Settlement) | \$84                 |
| Niaspan                        | Nicotinic Acid Derivatives                            | Abbott               | 2013-Q3 (Settlement) | \$1,114              |
| Temodar                        | Alkylating Agents                                     | Schering             | 2013-Q3 (Settlement) | \$383                |
| Bromday                        | Ophthalmics - Misc.                                   | Ista                 | 2013-Q3*             | \$4                  |
| Aciphex                        | Proton Pump Inhibitors                                | Eisai                | 2013-Q4*             | \$1,093              |
| Cymbalta                       | Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)  | Eli Lilly            | 2013-Q4*             | \$3,098              |
| Locoid Lipocream               | Corticosteroids - Topical                             | Triax Pharma         | 2013-Q4 (Settlement) | \$39                 |
| Oxycontin ER                   | Opioid Agonists                                       | Purdue               | 2013-Q4*             | \$3,162              |
| Rilutek                        | ALS Agents  | Sanofi Aventis       | 2013-Q4*             | \$51                 |
| Vanos                          | Corticosteroids - Topical                             | Medicis              | 2013-Q4*             | \$38                 |
| <b>2014</b>                    |   |                      |                      |                      |
| Atacand Tabs                   | Angiotensin II Receptor Antagonists                   | AstraZeneca          | 2014-Q1*             | \$165                |
| Loestrin 24                    | Combination Contraceptives - Oral                     | Warner Chilcott      | 2014-Q1 (Settlement) | \$495                |
| Rapamune Tabs                  | Immunosuppressive Agents                              | Pfizer               | 2014-Q1*             | \$200                |
| Actonel                        | Calcium Regulators - Misc.                            | Warner Chilcott      | 2014-Q2*             | \$832                |
| Celebrex                       | Nonsteroidal Anti-inflammatory Agents (NSAIDs)        | Pfizer               | 2014-Q2*             | \$1,740              |
| Lunesta                        | Non-Barbiturate Hypnotics                             | Spracor              | 2014-Q2 (Settlement) | \$791                |
| Malarone 250-100 MG            | Antimalarial Combinations                             | GlaxoSmithKline      | 2014-Q2*             | \$2                  |
| Nexium                         | Proton Pump Inhibitors                                | AstraZeneca          | 2014-Q2 (Settlement) | \$6,323              |
| Rapamune Solution              | Immunosuppressive Agents                              | Pfizer               | 2014-Q2*             | \$8                  |
| Xeloda                         | Antimetabolites                                       | Roche                | 2014-Q2*             | \$534                |
| Zemplar Caps                   | Metabolic Modifiers                                   | Abbott               | 2014-Q2*             | \$115                |
| Arthrotec                      | Nonsteroidal Anti-inflammatory Agents (NSAIDs)        | Pfizer               | 2014-Q3*             | \$137                |
| Avelox                         | Fluoroquinolones                                      | Bayer                | 2014-Q3*             | \$385                |

## Generic Prospective Pipeline Summary

### Launch Expected 2010 to 2014 - Sorted by Year and Quarter

**Disclaimer:** The information contained herein is compiled from a variety of sources and is provided for informational purposes only. Due to circumstances beyond Caremark's control, information related to prospective drug launch dates is subject to change without notice. This information should not be solely relied upon for decision making purposes. Products containing a Paragraph IV certification inherently involve risks and uncertainties that cannot be predicted or quantified. Actual results may differ from those expressed or implied in this report depending upon a number of factors. These factors include: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non-infringement of patents covering products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; and the ability of competitors to extend exclusivity periods for their products.

| Trade Name | Therapeutic Class           | Manufacturer    | Potential Launch | US Brand Sales (\$M) |
|------------|-----------------------------|-----------------|------------------|----------------------|
| Evista     | Hormone Receptor Modulators | Eli Lilly       | 2014-Q3*         | \$689                |
| Argatroban | Thrombin Inhibitors         | GlaxoSmithKline | 2014-Q4*         | \$148                |
| Copaxone   | Multiple Sclerosis Agents   | Teva            | 2014-Q4*         | \$2,051              |
| Humalog    | Insulin                     | Eli Lilly       | 2014-Q4*         | \$835                |
| Nexium IV  | Proton Pump Inhibitors      | AstraZeneca     | 2014-Q4*         | \$41                 |
| Novolog    | Insulin                     | Eli Lilly       | 2014-Q4*         | \$905                |

**\*\*Ortho Tri-Cyclen Lo - Teva settled, no additional product in marketplace until 12-31-15.**

**\*\*Pulmicort - Extremely limited quantities shipped into market on November 18, 2008. Product relaunched on December 15, 2009.**

Note: (1) \* Represents launch date including PED extension; (2) Annual brand sales are last twelve months (LTM); (3) Potential first to file ANDAs may entitle 6-months of marketing exclusivity to the content of this report may contain certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties